Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.820 +0.040 (+2.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gain Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Tuesday's after hours session: top gainers and losers ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate in Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected Mid-2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
Via Get News
News headline image
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
Via ACCESS Newswire
News headline image
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
Interim Analysis Expected End of 2Q 2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics To Participate in Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics To Present At Biotech Showcase 2025
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Initiation of Phase 1b Study of GT-02287 in Parkinson’s patients expected by end of 2024 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Gain Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.